Summarizes phase II and III data on cenobamate as adjunctive therapy for partial-onset seizures. Includes expert recommendations on adjusting dosing of other antiseizure medications when initiating cenobamate.
13 slides
Latest News
Switching from natalizumab to anti-CD20 agents
January 28, 2025A retrospective multicentre study (N=139) reports that a transition time <30 days when switching from natalizumab to an anti-CD20 agent is optimal for efficacy and safety (Bsteh et al. Eur J Neurol 2025;32:e16587). Mean age of patients at the time of switch was 38.8 years; median duration on natalizumab was 4.4 years. Read More
Fluid biomarkers during B cell-depleting therapy
January 17, 2025An analysis of the Swiss MS Cohort has found that routine monitoring of serum biomarkers can aid in predicting progression independent of relapse activity (PIRA) in patients during B cell-depleting therapy (Benkert et al. Ann Neurol 2025;97:104-115). Read More